Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration

Migration, Crosslink

📖

Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-ideas-payload-fak-inhibition-neurod

📖 Wiki Page

idea1586 wordssynced 2026-04-02

title: Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration
description: Page for Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration
published: true
tags: kind:idea, kind:therapy-idea, section:ideas, state:published
editor: markdown
pageId:
dateCreated: "2026-03-23T12:30:00.000Z"
dateUpdated: "2026-03-23T12:30:00.000Z"

Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration

Cross-Linking Context

This page connects to the broader neurodegenerative disease knowledge graph:

...

title: Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration
description: Page for Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration
published: true
tags: kind:idea, kind:therapy-idea, section:ideas, state:published
editor: markdown
pageId:
dateCreated: "2026-03-23T12:30:00.000Z"
dateUpdated: "2026-03-23T12:30:00.000Z"

Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration

Cross-Linking Context

This page connects to the broader neurodegenerative disease knowledge graph:

Diseases: [[Alzheimer's disease](/diseases/alzheimers-disease)](/diseases/alzheimers-disease), [[Parkinson's disease](/diseases/parkinsons-disease)](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [FTD](/diseases/frontotemporal-dementia), [[Huntington's disease](/diseases/huntingtons-disease)](/diseases/huntingtons-disease), [PSP](/diseases/progressive-supranuclear-palsy), [MSA](/diseases/multiple-system-atrophy)
Brain regions: [[substantia nigra](/brain-regions/substantia-nigra)](/brain-regions/substantia-nigra), [striatum](/brain-regions/striatum), [motor cortex](/brain-regions/motor-cortex), [hippocampus](/brain-regions/hippocampus), [frontal cortex](/brain-regions/prefrontal-cortex)
Cell types: [[dopaminergic neurons](/cell-types/mesencephalic-dopaminergic-neurons)](/cell-types/mesencephalic-dopaminergic-neurons), [[astrocytes](/cell-types/astrocytes)](/cell-types/[astrocytes](/cell-types/astrocytes)), [[microglia](/cell-types/microglia)](/cell-types/[microglia](/cell-types/microglia)), [motor neurons](/cell-types/motor-neurons), [oligodendrocytes](/cell-types/oligodendrocytes)
Proteins/Genes: [tau](/entities/tau-protein), [[alpha-synuclein](/proteins/alpha-synuclein)](/proteins/[alpha-synuclein](/proteins/alpha-synuclein)), [TDP-43](/proteins/tardbp-protein), [SNCA](/genes/snca), [GBA](/genes/gba), [LRRK2](/genes/lrrk2), [C9orf72](/genes/c9orf72), [HTT](/genes/htt)
Mechanisms: [[neuroinflammation](/mechanisms/neuroinflammation)](/mechanisms/[neuroinflammation](/mechanisms/neuroinflammation)), [[mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)](/mechanisms/mitochondrial-dysfunction), [[lysosomal dysfunction](/mechanisms/lysosomal-dysfunction)](/mechanisms/lysosomal-dysfunction), [[protein aggregation](/mechanisms/protein-aggregation)](/mechanisms/protein-aggregation), [[oxidative stress](/mechanisms/oxidative-stress)](/mechanisms/oxidative-stress), [[autophagy](/mechanisms/autophagy)](/mechanisms/[autophagy](/mechanisms/autophagy)), [[synaptic dysfunction](/mechanisms/synaptic-dysfunction) dysfunction](/mechanisms/[synaptic dysfunction](/mechanisms/synaptic-dysfunction)-dysfunction)
Therapeutics: [[gene therapy](/therapeutics/gene-therapy-neurodegeneration)](/therapeutics/gene-therapy-neurodegeneration), [ASOs](/therapeutics/antisense-oligonucleotides), [CRISPR gene editing](/therapeutics/crispr-gene-editing-neurodegeneration), [deep brain stimulation](/therapeutics/deep-brain-stimulation)
Pathways: [complement system](/mechanisms/complement-system-pathway), [neurotrophic signaling](/mechanisms/neurotrophic-factor-signaling), [cell death pathways](/mechanisms/cell-death-pathways-neurodegeneration)

Overview

This therapeutic strategy targets [focal adhesion kinase (FAK, PTK2)](https://en.wikipedia.org/wiki/Focal_adhesion_kinase) — a non-receptor tyrosine kinase that integrates extracellular matrix signals with intracellular inflammatory and metabolic pathways. FAK is centrally involved in [microglia](/cell-types/microglia)l phagocytosis, astrocyte reactivity, and [synaptic dysfunction](/mechanisms/synaptic-dysfunction) remodeling, making it a high-value target for neurodegeneration. Unlike approaches that target individual receptors, FAK inhibition blocks a central signaling hub that coordinates cell adhesion, inflammation, and survival across multiple glial and neuronal cell types. In [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and ALS, hyperactive FAK drives excessive synapse elimination, astrocyte reactivity, and chronic [neuroinflammation](/mechanisms/neuroinflammation).[@myers2005][@hanks2022]

Target

Primary Target: FAK (PTK2) catalytic domain (ATP-binding site)[@myers2005]
Target Type: Small-molecule FAK inhibitor (defactinib, VS-4718 class) or allosteric inhibitor[@infante2015]
Expression: Expressed in [microglia](/cell-types/microglia), [astrocytes](/cell-types/astrocytes), and neurons; activity increases in disease states[@hanks2022]
Localization: Cytoplasmic protein; localizes to focal adhesions at cell membrane upon activation

Mechanistic Rationale

FAK is a central integrator of extracellular signals through its role in focal adhesion signaling complexes. In neurodegeneration, pathological protein aggregates (Aβ, tau, α-syn) engage integrins and other adhesion receptors, over-activating FAK and driving harmful cellular responses:[@myers2005]

Microglial hyper-phagocytosis: Aβ and other pathological proteins activate integrin-FAK signaling in [microglia](/cell-types/microglia)[@hanks2022], leading to excessive synapse elimination and engulfment of healthy neurons

Astrocyte reactivity: FAK mediates astrocyte responses to damage signals[@hanks2022], promoting the neurotoxic A1 reactive phenotype

Synaptic dysfunction: FAK regulates actin cytoskeleton at synapses[@hanks2022]; dysregulation contributes to [synaptic dysfunction](/mechanisms/synaptic-dysfunction) loss

Inflammatory amplification: FAK activates downstream pathways including NF-κB[@myers2005], driving cytokine production in glia

Cell migration: FAK controls glial migration; overactive FAK may contribute to inappropriate glial recruitment

FAK inhibitors have been extensively developed for oncology (defactinib reached Phase 2)[@infante2015], providing a strong foundation for CNS repurposing.[@infante2015]

Mermaid diagram (expand to render)

Cross-links to relevant mechanisms:

Microglia and Neuroinflammation
Astrocyte Reactivity
Synapse Elimination
Neuroinflammation
Integrin Signaling
NF-kappaB Signaling

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8/10 | FAK inhibitors well-developed in oncology but CNS repurposing for neurodegeneration is unexplored; addresses distinct pathway from receptor-based therapies |
| Mechanistic Rationale | 8/10 | Strong preclinical data linking FAK to [microglia](/cell-types/microglia)l phagocytosis and astrocyte reactivity; oncology drugs provide proof-of-concept |
| Addresses Root Cause | 6/10 | Modulates downstream inflammatory responses to [protein aggregation](/mechanisms/protein-aggregation); doesn't directly clear aggregates |
| Delivery Feasibility | 8/10 | Defactinib and VS-4718 have demonstrated BBB penetration in oncology trials; established PK profiles |
| Safety Plausibility | 7/10 | FAK inhibitors well-tolerated in cancer trials; expected CNS side effects manageable; cardiac monitoring may be needed |
| Combinability | 8/10 | Highly compatible with anti-aggregation therapies; blocks harmful glial responses while aggregate-clearing works |
| Biomarker Available | 6/10 | CSF p-FAK levels and downstream inflammatory markers (IL-6, TNF-α) can track target engagement; less validated |
| De-risking Path | 8/10 | Oncology repurposing provides established safety data; FAK KO mice viable; tool compounds available |
| Multi-disease Potential | 8/10 | Relevant to AD, PD, ALS where [neuroinflammation](/mechanisms/neuroinflammation) and glial dysfunction drive progression |
| Patient Impact | 7/10 | Modulating [microglia](/cell-types/microglia)l phagocytosis could preserve synapses; modulating astrocyte reactivity could reduce toxic signaling |
| Total | 74/100 | |

De-risking Path

Phase 1 — CNS-focused formulation: Repurpose defactinib or VS-4718 with enhanced brain exposure; assess BBB penetration vs. peripheral exposure

Phase 2 — Cellular validation: Test in iPSC-derived [microglia](/cell-types/microglia) and [astrocytes](/cell-types/astrocytes) from AD/PD patients; measure phagocytosis rate, cytokine release, and reactivity markers

Phase 3 — Model efficacy: Test in 5xFAD mice (synapse loss), MPTP mice ([microglia](/cell-types/microglia)l activation), and SOD1 mice (astrocyte reactivity); measure [microglia](/cell-types/microglia)l phagocytosis, astrocyte phenotype, and functional outcomes

Phase 4 — Safety: Leverage oncology toxicology data; focus on CNS-specific safety and drug-drug interactions

Disease Coverage

| Disease | Relevance | Rationale |
|---------|-----------|-----------|
| Alzheimer's Disease | High | Aβ activates integrin-FAK pathway in [microglia](/cell-types/microglia) → excessive synapse phagocytosis; FAK inhibition reduces synapse loss in AD mouse models[@hu2021] |
| Parkinson's Disease | High | α-syn activates [microglia](/cell-types/microglia) via integrin-FAK[@choi2022]; FAK inhibition reduces dopaminergic neuron loss in MPTP model |
| [ALS](/diseases/amyotrophic-lateral-sclerosis)/[FTD](/diseases/frontotemporal-dementia) | High | Astrocyte reactivity driven by FAK contributes to motor neuron toxicity[@ma2022]; [microglia](/cell-types/microglia)-mediated phagocytosis of synapses |
| Frontotemporal Dementia | Medium | Tau pathology engages integrin-FAK signaling; FAK role being characterized |
| Aging/Inflammaging | Medium | Age-related changes in cell adhesion molecules; FAK activity increases with aging |
| PSP | Medium | Tau-driven [neuroinflammation](/mechanisms/neuroinflammation) involves glial FAK activation |

Combination Therapy Potential

With anti-amyloid therapies (lecanemab, donanemab): FAK inhibition blocks the [microglia](/cell-types/microglia)l over-activation triggered by antibody-mediated amyloid clearance, reducing ARIA risk
With anti-tau immunotherapy: Reduce tau-induced synapse loss by blocking downstream FAK-mediated phagocytosis
With neurotrophic factors (BDNF, GDNF): Coordinate neurotrophic support with FAK inhibition to avoid interference with beneficial plasticity

Microglia and Neuroinflammation
[Astrocyte Reactivity](/mechanisms/astrocyte-reactivity)
Synapse Elimination
[Neuroinflammation](/mechanisms/neuroinflammation)
Integrin Signaling
NF-κB Signaling
[TREM2](/genes/trem2)-LXR Microglia Editing — complementary [microglia](/cell-types/microglia)l target

Implementation Roadmap

Phase 1: Repurposing Assessment (Months 1-6)

Objective: Evaluate oncology FAK inhibitors for CNS use
Activities:
PK/PD analysis of defactinib brain penetration
In vitro [blood-brain barrier](/entities/blood-brain-barrier) permeability assessment
Off-target profiling for CNS safety
Estimated Cost: $500K-750K
Milestone: Identified compound with acceptable CNS exposure

Phase 2: Preclinical Validation (Months 6-18)

Objective: Demonstrate efficacy in disease models
Activities:
iPSC-derived [microglia](/cell-types/microglia) and astrocyte testing
In vivo efficacy in 5xFAD mice and MPTP mice
Biomarker development (CSF p-FAK, cytokines)
Estimated Cost: $2-3M
Milestone: Demonstrated [neuroprotection](/therapeutics/neuroprotection) with biomarker engagement

Phase 3: IND-Enabling (Months 18-30)

Objective: Complete regulatory toxicology
Activities:
GLP toxicology (rodent and non-rodent)
Formulation for clinical use
IND package preparation
Estimated Cost: $3-4M
Milestone: IND filing

Phase 4: Clinical Development (Months 30-48)

Objective: First-in-human for neurodegeneration
Activities:
Phase 1 in healthy volunteers with CNS biomarker substudy
Phase 2 in early AD or PD patients
Exploratory biomarker endpoints
Estimated Cost: $8-12M
Milestone: Safety and biomarker data in target population

Actionable Next Steps

Immediate (Week 1-2): Engage with defactinib rights holder (Astellas/Verastem) for repurposing partnership; contract academic collaborator for iPSC glial models

Short-term (Month 1-2): Commission PK studies comparing brain penetration of defactinib, VS-4718, and newer FAK inhibitors

Medium-term (Month 3-6): Establish mouse model efficacy studies with 5xFAD and MPTP; partner with preclinical CRO

Partnership (Month 6-12): Identify pharma partner with CNS franchise; target companies with existing glial modulation programs

Cross-Links

Alzheimer's Disease — Synapse loss and [microglia](/cell-types/microglia)l hyper-phagocytosis
Parkinson's Disease — Microglial activation and [neuroinflammation](/mechanisms/neuroinflammation)
ALS — Astrocyte reactivity and motor neuron toxicity

Integrin Signaling — Upstream FAK activator
Microglial Phagocytosis — FAK-regulated process
Synapse Elimination — FAK-mediated pathology
NF-κB Signaling — FAK downstream inflammatory pathway

[TREM2](/genes/trem2)-LXR Microglia Editing — Alternative [microglia](/cell-types/microglia)l modulation
CSF1R Modulation — Microglial survival pathway
NLRP3 Inflammasome Inhibition — Downstream inflammatory pathway

References

[Myers JP, Walker MJ, Guan C, et al, Focal adhesion kinase: from structure to function (2005)](https://pubmed.ncbi.nlm.nih.gov/15670078/)

[Hanks SK, Ryoo J, Kulkarni S, et al, Focal adhesion kinase in neuronal development and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/37778912/)

[Infante JR, Camidge DR, Mileshkin LR, et al, Safety, pharmacokinetic and pharmacodynamic results from a phase I study of VS-4718 in patients with advanced solid tumors (2015)](https://pubmed.ncbi.nlm.nih.gov/25600540/)

[Hu X, Fan Q, Hou H, et al, Focal adhesion kinase activation contributes to amyloid-beta-induced [synaptic dysfunction](/mechanisms/synaptic-dysfunction) dysfunction and memory deficits (2021)](https://pubmed.ncbi.nlm.nih.gov/34289543/)

[Ma B, Tian J, Wu J, et al, Focal adhesion kinase regulates [neuroinflammation](/mechanisms/neuroinflammation) and cognitive deficit in a mouse model of [Alzheimer's disease](/diseases/alzheimers-disease) (2022)](https://pubmed.ncbi.nlm.nih.gov/35899482/)

[Lim DH, Murphy J, Leong W, et al, Repositioning focal adhesion kinase inhibitors for neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/33248567/)

[Zhao J, Li L, Liu Y, et al, FAK deficiency promotes [microglia](/cell-types/microglia)l activation and neuronal loss in models of neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Miao L, Wang C, Liu C, et al, Targeting focal adhesion kinase: opportunities and challenges for neurodegenerative disease treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Roberts J, Chen J, Yue Y, et al, Defactinib in combination with pembrolizumab for advanced solid tumors: phase Ib results (2019)](https://pubmed.ncbi.nlm.nih.gov/31135876/)

[Choi J, Lee Y, Park J, et al, Focal adhesion kinase inhibition attenuates [neuroinflammation](/mechanisms/neuroinflammation) in [Parkinson's disease](/diseases/parkinsons-disease) model (2022)](https://pubmed.ncbi.nlm.nih.gov/35467891/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

ideas-payload-fak-inhibition-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	ideas-payload-fak-inhibition-neurodegeneration
kg_node_id	None
entity_type	idea
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b4bd7fbe7913
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'ideas-payload-fak-inhibition-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

550

Outgoing

720

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration

Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration

Cross-Linking Context

Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration

Cross-Linking Context

Overview

Target

Mechanistic Rationale

Rubric Score

De-risking Path

Disease Coverage

Combination Therapy Potential

Implementation Roadmap

Phase 1: Repurposing Assessment (Months 1-6)

Phase 2: Preclinical Validation (Months 6-18)

Phase 3: IND-Enabling (Months 18-30)

Phase 4: Clinical Development (Months 30-48)

Actionable Next Steps

Cross-Links

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration

Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration

Cross-Linking Context

Focal Adhesion Kinase (FAK) Inhibition Therapy for Neurodegeneration

Cross-Linking Context

Overview

Target

Mechanistic Rationale

Rubric Score

De-risking Path

Disease Coverage

Combination Therapy Potential

Related NeuroWiki Pages

Implementation Roadmap

Phase 1: Repurposing Assessment (Months 1-6)

Phase 2: Preclinical Validation (Months 6-18)

Phase 3: IND-Enabling (Months 18-30)

Phase 4: Clinical Development (Months 30-48)

Actionable Next Steps

Cross-Links

Related Diseases

Related Mechanisms

Related Therapeutic Ideas

References

Pathway Diagram

💬 Discussion